7 August 2019 - AMAG Pharmaceuticals Inc’s treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder.

The therapy, Vyleesi, was approved in June and will be available in September through the company’s specialty pharmacy distribution network that would deliver the treatment to patients’ homes.

Women will be able to buy a pack of four injectors of which one needs to be administered at least 45 minutes before anticipated sexual activity, the company said on Tuesday. It will compete with Sprout Pharmaceuticals’ Addyi, a once-daily pill.

Read Reuters article